STALICLA SA is a Swiss clinical-stage biopharmaceutical company developing precision-medicine approaches for neurodevelopmental and neuropsychiatric disorders. The company employs a multi-omics DEPI platform to identify patient subgroups and match them with targeted therapeutic candidates; its pipeline includes subgroup-matched programs such as STP1 for Autism Spectrum Disorder and STP7 for Substance Use Disorder, and it conducts clinical collaborations to advance these programs.
Leadership & Board
Current Number of Employees23
Current LinkedIn Followers5,694
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$3M
Total Amount Raised$3M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$3M
Latest Funding Amount$3M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
STALICLA had 23 employees as of May 25, 2026. The number of employees decreased by 1 (4.17%) week-over-week.
23Latest Employee Count
1(-4.17%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
STALICLA had 5,694 followers as of May 25, 2026. The number of followers increased by 6 (0.11%) week-over-week.
5,694Latest Followers Count
6(0.11%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.